BRIEF — aTyr Pharma Announces Alignment With FDA On Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis

Sept 24 (Reuters) — aTyr Pharma Inc: Atyr Pharma Announces Alignment With Fda On Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis Atyr Pharma - To Initiate Study-related Activities In Q4 2026 Source text:... Further company coverage: ATYR.O (Reuters.Briefs@thomsonreuters.com;)